High-intensity focused ultrasound for the treatment of prostate cancer: A prospective trial with long-term follow-up

References

• European Cancer Observatory. Cancer fact sheets. Available from http://eco.iarc.fr/eucan/CancerOne.aspx?Cancer=29&Gender=1. Accessed 19 July 2010.
   Google Scholar
• Lynn LG, Putnam TJ. Histology of cerebral lesions produced by focused ultrasound. Am J Pathol 1944;20:637–49.
   PubMedGoogle Scholar
• EDAP TMS website. Available from http://www.edap-tms.com/. Accessed 10 February 2010.
   Google Scholar
• Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res 1995;55:3346–51.
   PubMed Web of Science ®Google Scholar
• Warmuth M, Johansson T, Mad P. Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer. Eur Urol 2010;58:803–15.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent – update 2013. Eur Urol 2014;65:124–37.
   PubMed Web of Science ®Google Scholar
• American Urological Association. Guideline for the management of clinically localized prostate cancer: 2007 update. Available from http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=pc. Accessed 10 February 2010.
   Google Scholar
• Uchida T, Shoji S, Nakano M, Hongo S, Nitta M, Murota A, et al. Transrectal high-intensity focused ultrasound for the treatment of localized prostate cancer: eight-year experience. Int J Urol 2009;16:881–6.
   PubMed Web of Science ®Google Scholar
• Mearini L, D’Urso L, Collura D, Zucchi A, Costantini E, Formiconi A, et al. Visually directed transrectal high intensity focused ultrasound for the treatment of prostate cancer: a preliminary report on the Italian experience. J Urol 2009;181:105–11.
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–74.
   PubMed Web of Science ®Google Scholar
• Illing RO, Leslie TA, Kennedy JE, Calleary JG, Odgen CW, Emberton M. Visually directed high-intensity focused ultrasound for organ-confined prostate cancer: a proposed standard for the conduct of therapy. BJU Int 2006;98:1187–92.
   PubMed Web of Science ®Google Scholar
• Leslie TA, Illing RO, Kennedy Calleary JE, D’Urso L, Mearini L, Brewster SF, et al. Conduct of HIFU therapy for low to moderate risk, organ confined prostate cancer with the Sonablate®-500 System – results of consensus meeting. Available from http://www.ukhifu.com/pdfs/ConsensusofOpinionauthorchange.pdf. Accessed 2006.
   Google Scholar
• Roach MIII, Hanks G, Thames HJr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965–74.
   PubMed Web of Science ®Google Scholar
• Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial. J Natl Cancer Inst 2008;100:1144–54.
   PubMed Web of Science ®Google Scholar
• Klotz L. Active surveillance: patient selection. Curr Opin Urol 2013;23:239–44.
   PubMedGoogle Scholar
• Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, et al. Multi-institutional analysis of long-term outcome for stage T1–T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007;67:327–33.
   PubMed Web of Science ®Google Scholar
• Cohen JK, Miller RJJr, Ahmed S, Lotz MJ, Baust J. Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Oncology 2008;71:515–18.
   Google Scholar
• Blana A, Walter B, Rogenhofer S, Wieland WF. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 2004;63:297–300.
   PubMed Web of Science ®Google Scholar
• Ripert T, Azémar MD, Ménard J, Barbe C, Messaoudi R, Bayoud Y, et al. Six years’ experience with high-intensity focused ultrasonography for prostate cancer: oncological outcomes using the new “Stuttgart” definition for biochemical failure. BJU Int 2011;107:1899–905.
   PubMedGoogle Scholar
• Crouzet S, Chapelon JY, Rouvière O, Mege-Lechevallier F, Colombel M, Tonoli-Catez H, et al. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients. Eur Urol 2014;65:907–14.
   PubMed Web of Science ®Google Scholar
• Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C, et al. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol 2008;53:1194–203.
   PubMed Web of Science ®Google Scholar
• Crouzet S, Rebillard X, Chevallier D, Rischmann P, Pasticier G, Garcia G, et al. Multicentric oncologic outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients. Eur Urol 2010;58:559–66.
   PubMed Web of Science ®Google Scholar
• Shoji S, Nakano M, Nagata Y, Usui Y, Terachi T, Uchida T. Quality of life following high-intensity focused ultrasound for the treatment of localized prostate cancer: a prospective study. Int J Urol 2010;17:715–19.
   PubMedGoogle Scholar
• Uchida T, Ohkusa H, Nagata Y, Hyodo T, Satoh T, Irie A. Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int 2006;97:56–61.
   PubMed Web of Science ®Google Scholar
• Blana A, Brown SC, Chaussy C, Conti GN, Eastham JA, Ganzer R, et al. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int 2009;104:58–62.
   PubMedGoogle Scholar
• Ganzer R, Robertson CN, Ward JF, Brown SC, Conti GN, Murat FJ, et al. Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria – analysis from the @-Registry. BJU Int 2011;108:196–201.
   PubMedGoogle Scholar
• Ganzer R, Fritsche HM, Brandtner A, Bründl J, Koch D, Wieland WF, et al. Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer. BJU Int 2013;112:322–9.
   PubMedGoogle Scholar
• Uchida T, Illing RO, Cathcart PJ, Emberton M. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int 2006;98:537–9.
   PubMed Web of Science ®Google Scholar
• Shoji S, Uchida T, Nakamoto M, Kim H, de Castroabreu AL, Leslie S, et al. Prostatic swelling and shift during high-intensity focused ultrasound: implication for targeted focal therapy. J Urol 2013;190:1224–32.
   PubMed Web of Science ®Google Scholar
• Blana A, Rogenhofer S, Ganzer R, Lunz JC, Schostak M, Wieland WF, et al. Eight years’ experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. Urology 2008;72:1329–38.
   PubMed Web of Science ®Google Scholar